Desjardins, A., Reardon, D. A., Peters, K. B., Herndon, J. E., Gururangan, S., Norfleet, J., … Vredenburgh, J. J. (2011). PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS. NEURO-ONCOLOGY, 13, 90–90.

Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, Sridharan Gururangan, Julie Norfleet, Henry S. Friedman, and James J. Vredenburgh. “PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS.” NEURO-ONCOLOGY 13 (November 1, 2011): 90–90.

Desjardins A, Reardon DA, Peters KB, Herndon JE, Gururangan S, Norfleet J, et al. PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS. NEURO-ONCOLOGY. 2011 Nov 1;13:90–90.

Desjardins, Annick, et al. “PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS.” NEURO-ONCOLOGY, vol. 13, OXFORD UNIV PRESS INC, Nov. 2011, pp. 90–90.

Desjardins A, Reardon DA, Peters KB, Herndon JE, Gururangan S, Norfleet J, Friedman HS, Vredenburgh JJ. PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2011 Nov 1;13:90–90.